Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

eptember 30, 2009 general and administrative expenses increased to $2.7 million from $2.2 million in 2008. The increase in 2009 was primarily due to increased employee expenses and increased costs associated with operating as a public company.

The net loss for the third quarter increased to $2.4 million from $4.6 million in income in 2008. For the nine months ended September 30, 2009 the net loss increased to $9.4 million from $0.8 million in income in 2008. The net income recognized in both 2008 periods was primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal of tax expense associated with the change in capital structure of OncoGenex Technologies, both non-cash items.

The third quarter and nine months ended September 30, 2008 also included $0.4 million and $2.0 million, respectively, in preferred share accretion, a non-cash item, which did not recur in the third quarter or nine months ended September 30, 2009, as subsequent to the reverse takeover there are no preferred shares outstanding.

The Company had $12.5 million in cash, cash equivalents and short-term investments as of September 30, 2009, compared to $12.4 million in cash, cash equivalents and short-term investments as of December 31, 2008.

The Company had 6,034,959 shares outstanding as of November 1, 2009. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations through at least the third quarter of 2010, including:

    -   completing partnering discussions related to OGX-011;
    -   completing follow-up monitoring visits related to completed phase 2
        clinical trials of OGX-011;
    -   completing follow-up monitoring visits related to the Phase 1
        clinical trial evaluating OGX-427 as a monotherapy in patients with
        solid tumors and continuing evaluation of OGX-427 in combination with
        docetaxe
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... bioactive compounds and metabolic processes, is pleased to announce the ... directors. Ms. Nola E. Masterson , a ... board effective September 17, 2014. "We,re very ... our board," states Andrew Dahl , President and CEO. ...
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... 2014 OMICS Group International invites ... participate in the ‘Open Access Week’ by actively ... OMICS Group Pharma Journals from 20-26th October, ... fastest emerging Sciences, accelerating with a tremendous speed ... the globe. The industry is gearing with innovation ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Colo., Oct. 19 The Davis Phinney Foundation ( ... provide information and tools that help people to live ... a new exercise DVD: " Exercise and Parkinson,s: Questions ... a panel of movement disorder experts in the fields ...
... SAINT PAUL, Minn., Oct. 19 Cellectis plant ... of Cellectis (Alternext: ALCLS), announced today that it ... Inc. for plant transformation technologies. The agreement provides ... Midwest,s Aerosol Beam Injector (ABI) technology for precise ...
... Reportlinker.com announces that a new market ... Global Automated And Rapid ... http://www.reportlinker.com/p092467/Global-Automated-And-Rapid-Microbiological-Tests-Industry.html This report analyzes ... Microbiological Tests in US$ Million by the ...
Cached Biology Technology:Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 2Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 3Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 4Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds 2Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds 3Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 2Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 3Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 4Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 5Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 6Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 7Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 8Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 9Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 10Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 11Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 12Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 13Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 14Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 15Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 16Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 17Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 18Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 19Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 20Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 21Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 22Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 23Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 24Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry 25
(Date:9/18/2014)... ability to acquire and creatively manipulate spoken language is ... the past 6 million years of human evolution to ... the best candidate gene we now have," says Wolfgang ... In his efforts to understand the molecular biological basis ... forward. The results of his latest study, undertaken in ...
(Date:9/18/2014)... racial and ethnic groups describe losing eyesight as ... life, more so than other conditions including: loss ... African-Americans, 49% of non-Hispanic whites, 43% of Asians ... or ailment is the worst that could happen ... by AIDS/HIV. Hispanics and Asians ranked cancer ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2
... explore one of the most critical health/environment intersections how ... diabetes and contribute to the problems of obesity Michigan ... by the Environmental Protection Agency. A five-year, $8 million ... Professor of pathobiology and diagnostic investigation in the College of ...
... Starting rehabilitation sooner following knee arthroplasty surgery could ... physical therapy within 24 hours of surgery can improve ... well as cut hospital stays, according to new research ... SAGE. Mindful of the trend towards discharging patients ...
... CA "Pluripotent" stem cellswhich have the potential to mature ... for their role in treating a vast array of human ... a team of Scripps Research Institute scientists has created a ... for researchers to determine whether their cell lines are normal ...
Cached Biology News:Hold your breath: Air pollution plays role in cardiac, metabolic diseases 2Rehabilitation within a day of knee replacement pays off 2Scripps Research scientists develop new test for 'pluripotent' stem cells 2
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Biology Products: